Ginkgo Bioworks Holdings (DNA) Non-Current Deffered Revenue (2020 - 2026)

Ginkgo Bioworks Holdings' Non-Current Deffered Revenue history runs 7 years deep, the most recent figure standing at $77.9 million for Q1 2026.

• Quarterly Non-Current Deffered Revenue fell 3.09% year-over-year to $77.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $77.9 million (down 3.09% YoY) and the FY2025 annual result came in at $75.2 million, down 23.89% from the prior year.
• Non-Current Deffered Revenue was $77.9 million for Q1 2026 at Ginkgo Bioworks Holdings, up from $75.2 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $179.9 million in Q2 2023 and bottomed at $74.1 million in Q3 2025.
• A 5-year average of $131.8 million and a median of $152.9 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue soared 181.87% — and 2025, when it slumped 51.6%.
• Ginkgo Bioworks Holdings' Non-Current Deffered Revenue stood at $174.8 million in 2022, then decreased by 9.56% to $158.1 million in 2023, then tumbled by 37.5% to $98.8 million in 2024, then retreated by 23.89% to $75.2 million in 2025, then grew by 3.61% to $77.9 million in 2026.
• Business Quant data shows DNA's Non-Current Deffered Revenue at $77.9 million in Q1 2026, $75.2 million in Q4 2025, and $74.1 million in Q3 2025.